Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathalie Daaboul

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Current Oncology (Toronto, Ont.)|March 26, 2025
Lung Cancer: Targeted Therapy in 2025Nicole Bouchard, Nathalie Daaboul
Advances in Therapy|May 22, 2025
Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast DiscussionChristine M Bestvina, Chul Kim, Nathalie Daaboul
Expert Review of Anticancer Therapy|May 7, 2026
LUMINATE-101-Maccabi: a real-world study of treatment patterns and clinical outcomes in patients with non-squamous metastatic non-small cell lung cancer in an Israeli health maintenance organization (HMO)Sarah Sharman Moser, Alona Zer, Andre Hejazi, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation StrategiesParneet K Cheema, Kirstin A Perdrizet, Randeep S Sangha, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2020
High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort studyArielle Elkrief, Antoine Desilets, Neha Papneja, et al.
JTO Clinical and Research Reports|June 29, 2026
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY TrialNicolas Girard, Jonathan Goldman, Shun Lu, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2020
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre studyAntoine Desilets, Félix Blanc-Durand, Sally Lau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2024
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous <i>EGFR</i>-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY TrialD Ross Camidge, Jair Bar, Hidehito Horinouchi, et al.
Current Oncology (Toronto, Ont.)|June 2, 2021
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019Joanna Gotfrit, Rachel Goodwin, Timothy Asmis, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Oncology (Toronto, Ont.)|March 26, 2025
Lung Cancer: Targeted Therapy in 2025Nicole Bouchard, Nathalie Daaboul
Advances in Therapy|May 22, 2025
Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast DiscussionChristine M Bestvina, Chul Kim, Nathalie Daaboul
Expert Review of Anticancer Therapy|May 7, 2026
LUMINATE-101-Maccabi: a real-world study of treatment patterns and clinical outcomes in patients with non-squamous metastatic non-small cell lung cancer in an Israeli health maintenance organization (HMO)Sarah Sharman Moser, Alona Zer, Andre Hejazi, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation StrategiesParneet K Cheema, Kirstin A Perdrizet, Randeep S Sangha, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2020
High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort studyArielle Elkrief, Antoine Desilets, Neha Papneja, et al.
JTO Clinical and Research Reports|June 29, 2026
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY TrialNicolas Girard, Jonathan Goldman, Shun Lu, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2020
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre studyAntoine Desilets, Félix Blanc-Durand, Sally Lau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2024
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous <i>EGFR</i>-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY TrialD Ross Camidge, Jair Bar, Hidehito Horinouchi, et al.
Current Oncology (Toronto, Ont.)|June 2, 2021
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019Joanna Gotfrit, Rachel Goodwin, Timothy Asmis, et al.
Pageof 1